Jasper Therapeutics (NASDAQ:JSPR) Coverage Initiated at UBS Group

UBS Group assumed coverage on shares of Jasper Therapeutics (NASDAQ:JSPR) in a research report issued to clients and investors on Monday. The firm set a “neutral” rating and a $1.50 price target on the stock. UBS Group’s target price would suggest a potential upside of 21.95% from the stock’s previous close.

Other research analysts have also recently issued reports about the stock. Rodman & Renshaw initiated coverage on shares of Jasper Therapeutics in a research report on Tuesday, January 13th. They issued a “buy” rating and a $17.00 price objective on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Thursday, January 22nd. Six research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $16.94.

Jasper Therapeutics Stock Up 0.8%

Shares of NASDAQ JSPR opened at $1.23 on Monday. The firm has a market capitalization of $34.42 million, a P/E ratio of -0.21 and a beta of 3.08. The stock’s 50-day simple moving average is $1.38 and its two-hundred day simple moving average is $1.84. Jasper Therapeutics has a twelve month low of $1.11 and a twelve month high of $7.19.

Institutional Investors Weigh In On Jasper Therapeutics

Hedge funds have recently made changes to their positions in the business. Engineers Gate Manager LP bought a new position in shares of Jasper Therapeutics during the 4th quarter valued at $26,000. Panagora Asset Management Inc. purchased a new position in shares of Jasper Therapeutics in the fourth quarter worth about $35,000. Acadian Asset Management LLC purchased a new stake in Jasper Therapeutics during the 1st quarter valued at about $46,000. Voleon Capital Management LP purchased a new position in Jasper Therapeutics in the 3rd quarter worth approximately $50,000. Finally, Marex Group plc bought a new stake in Jasper Therapeutics in the second quarter valued at approximately $74,000. 79.85% of the stock is currently owned by institutional investors.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.